Robert Lazar, MD
Allergy & Immunology · Traverse City, MINPI 1831150770
Payments from drug & device makers
Across 1,181 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$15K
- Pharming Healthcare, Inc.$5K
- AstraZeneca$4K
- GSK$2K
- Genentech USA, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $6K from 30 others
What the payments were for
- Consulting fees$4,73113%
- Speaking & faculty fees$11,38532%
- Travel & lodging$1,8605%
- Food & beverage$17,32949%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 114 | $14,599 |
| Pharming Healthcare, Inc. | 115 | $5,394 |
| AstraZeneca | 135 | $3,612 |
| GSK | 253 | $2,322 |
| Genentech USA, Inc. | 78 | $1,987 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 81 | $1,053 |
| Pfizer | 84 | $880 |
| Novartis | 50 | $848 |
| Sanofi | 40 | $729 |
| Amgen(2 entities) | 39 | $628 |
| Shire North American Group Inc | 28 | $270 |
| Teva Pharmaceuticals USA, Inc. | 13 | $209 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $185 |
| Boehringer Ingelheim | 8 | $155 |
| Biocryst US Sales Co., LLC | 9 | $153 |
| Ionis Pharmaceuticals, Inc. | 6 | $149 |
| Mylan Specialty L.p. | 9 | $135 |
| Kaleo, Inc. | 8 | $123 |
| Sunovion Pharmaceuticals Inc. | 16 | $119 |
| Blueprint Medicines Corporation | 4 | $82 |
| Grifols USA, LLC | 5 | $82 |
| Nestle Healthcare Nutrition Inc. | 3 | $68 |
| ADMA Biomanufacturing LLC | 4 | $64 |
| Merck | 4 | $60 |
| Bio Products Laboratory USA, Inc. | 4 | $59 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| AbbVie | 2 | $34 |
| Octapharma USA, Inc. | 2 | $31 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Biocryst Pharmaceuticals, Inc. | 1 | $17 |
| LEO Pharma Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,408 in reported general payments places this provider in the 80th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 38 | $1,930,120 |
| HaegardaC1 Esterase Inhibitor | 30 | $705,367 |
| Dupixent PenDupilumab | 153 | $667,955 |
| OrladeyoBerotralstat Hydrochloride | 12 | $528,931 |
| XolairOmalizumab | 83 | $239,410 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 212 | $170,307 |
| NucalaMepolizumab | 45 | $164,162 |
| Dupixent SyringeDupilumab | 18 | $68,126 |
| Fasenra PenBenralizumab | 12 | $63,671 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $38,961 |
| Ipratropium Bromide | 416 | $15,148 |
| DuleraMometasone/Formoterol | 31 | $14,903 |
| Epinephrine | 51 | $13,834 |
| Qvar RedihalerBeclomethasone Dipropionate | 34 | $13,132 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 30 | $12,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,053 | $1,930,12038 claims |
| CSL BehringHaegarda | $14,599 | $705,36730 claims |
| Biocryst US Sales Co., LLCOrladeyo | $153 | $528,93112 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $2,322 | $385,972403 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Pulmicort Flexhaler | $3,612 | $31,19282 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl | $209 | $16,71845 claims |
| MerckDulera, Asmanex | $60 | $16,38344 claims |
| Boehringer IngelheimSpiriva Respimat | $155 | $7,34413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Traverse City
- Laura HoweTraverse City$13K
- Jeffrey LefleinYpsilanti$7.9M
- Cem AkinNorthville$3M
- Alan BaptistAnn Arbor$2.5M
- Suresh AnneFlint$1.1M
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Rajan RavikumarBrighton$661K
- Georgiana SandersAnn Arbor$607K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.